Physician profile
Daniel Eshaghian
NPI 1275943128
$5,058.60
in general payments reported to CMS, 2019-2025
25 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $171 · 2021: $1,057 · 2022: $877 · 2023: $338 · 2024: $934 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,424 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.73 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $888.19 | 2019-2025 | Xifaxan |
| Abbvie INC. | $715.89 | 2020-2025 | |
| Janssen Biotech, INC. | $628.40 | 2020-2025 | Tremfya, Simponi, Stelara |
| Janssen Scientific Affairs, LLC | $334.33 | 2019-2021 | |
| Genzyme Corporation | $297.75 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $292.06 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $276.36 | 2022-2024 | Linzess |
| Qol Medical, LLC | $198.17 | 2024-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $195.69 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $187.05 | 2024-2025 | Resmetirom, Rezdiffra |
| Intercept Pharmaceuticals, INC. | $154.52 | 2021-2022 | |
| Boston Scientific Corporation | $126.17 | 2022 | |
| Portola Pharmaceuticals, LLC | $123.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $106.45 | 2021 | |
| Ethicon US, LLC | $91.72 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $91.57 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.76 | 2021-2025 | Entyvio |
| Gilead Sciences, INC. | $76.67 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $54.32 | 2025 | Iqirvo |
| Pfizer INC. | $38.16 | 2024-2025 | |
| Braintree Laboratories, INC. | $29.04 | 2022-2023 | Sutab |
| Mirum Pharmaceuticals, INC. | $21.83 | 2024 | Livmarli |
| Celgene Corporation | $20.92 | 2023 | Zeposia |
| Olympus America INC. | $17.58 | 2021 | |
| Redhill Biopharma INC. | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Eshaghian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.